

ILLUMINA INC  
Form 8-K  
July 09, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
Form 8-K  
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): July 9, 2014  
Illumina, Inc.  
(Exact name of registrant as specified in its charter)

001-35406  
(Commission File Number)

Delaware  
(State or other jurisdiction of incorporation)

33-0804655  
(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122  
(Address of principal executive offices) (Zip code)

(858) 202-4500  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

Genomics England, set up by the UK Government to deliver the pioneering 100,000 Genomes Project, has selected Illumina Cambridge Ltd, a subsidiary of Illumina Inc, as the preferred partner for the sequencing element of the project. The parties intend to work quickly towards a definitive agreement.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ILLUMINA, INC.

Date: July 9, 2014

By: /s/ Marc A. Stapley  
Marc A. Stapley  
Senior Vice President and Chief Financial Officer